-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Preface
Cytokines and their receptors have been extensively studied as tumor targets or therapeutic strategies, and have been used for the treatment of cancer patients for more than 40 years
1
Cytokines and tumor microenvironment
Cytokines are secreted by a variety of cell types and are regulators
Cytokines are key proteins for signaling in the tumor microenvironment (TME) and are multi-potent
Role of cytokines in the tumor microenvironment (from references)
2
Cytokines occur with cancer
Chronic inflammation is one
Mechanism of carcinogenic action of interleukins (from references)
3
Cytokines and cancer treatment
Through more than 40 years of research on cytokines, it has been confirmed that it helps anti-tumor immunity, and it has been tried to be used in disease treatment
Key cytokines in clinical research in cancer therapy (from references)
With the widespread use of anti-cytokine therapy, especially anticytokine therapy targeting TNF, IL-6 and IL-1, in some inflammatory and autoimmune diseases, preclinical research has provided a basis
Most clinical trials of the anti-cytokine mAb are early, dose-exploratory safety studies
conducted in patients with advanced cancer.
These drug monotherapy have limited or no observed efficacy, but the treatment is generally well tolerated and there are few
safety issues.
Therefore, these antagonists are currently being used in combination with other immunotherapy and cancer treatments
.
Major cytokines or their receptor antagonists in clinical research in cancer therapy (from the references)
In summary, cytokines are key elements
in coordinating TME and controlling tumor-immune cell interactions.
Although there are still many obstacles to be overcome on the road to clinical development, in-depth study of cytokines in tumor biology can help better understand their mechanism of action and contribute to
the development of new treatment strategies.
And the new generation of cytokine therapy for cancer has made a lot of exciting results in preclinical and clinical research, so cytokines can be expected
in the future of tumor immunotherapy.
✦ Advantages of Yiqiao Shenzhou cytokine products
01
High purity
Human IL-1β recombinant protein: 10139-HNAE
SDS-PAGE and SEC-HPLC test results: above 95% purity
02
High activity
GMP grade IL-6 recombinant protein: GMP-10395-HNAE
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells.
The ED50 for this effect is 0.
1-0.
8 ng/mL.
The specific activity of recombinant human IL-6 is >100,000 IU/μg, which is calibrated against human IL-6 WHO International Standard (NIBSC code: 89/548).
03
High batch-to-batch consistency
Human TNF-alpha/TNFA protein: 10602-HNAE
Measured in a cytotoxicity assay using L929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D.
The ED50 for this effect is typically 3-30 pg/mL.
High-quality cytokine preparation technology of Yiqiao Shenzhou
At present, Yiqiao Shenzhou has developed more than 1,100 kinds of cytokine products, covering 240 cytokine targets, including interleukins, interferons, tumor necrosis factors, chemokines, growth factors, lymphocytes, etc
.
In order to obtain high-quality cytokine recombinant proteins, Yiqiao Shenzhou has successfully developed a platform for expression including baculovirus-insect cells, mammalian cells and prokaryotic proteins, with the ability to develop more than 1,000 new proteins per year, with production scales ranging from micrograms to kilograms
.
Among them, the baculovirus-insect cell expression platform is a eukaryotic expression system that uses baculovirus as a carrier to express exogenous proteins in insect cells, which has the characteristics of high expression efficiency, large capacity of inserted exogenous genes, no threat to operators and the environment, and can modify and process the expressed exogenous proteins after translation, so that the expressed proteins have biological activity
.
This system is suitable for the recombinant expression of different types of proteins and can also express multiple proteins
at the same time.
So, how do you confirm that the protein is suitable for baculovirus-insect cell expression platforms? How to design the program? In this lecture, Dr.
Zhang Xuejiao will share the experience of recombinant expression of baculovirus-insect cells based on practical cases, focusing on the construction strategy of baculovirus vectors, the expression of recombinant proteins and the optimization
of purification protocols.
【References】
1.
Glenn Dranoff, Cytokines in cancer pathogenesis and cancer therapy.
Nature Reviews Cancer, 2004
2.
Daria Briukhovetska, et al.
Interleukins in cancer: from biology to therapy.
Nature Reviews Cancer, 2021
3.
Propper DJ, Balkwill FR.
Harnessing cytokines and chemokines for cancer therapy.
Nature Reviews Clinical Oncology.
2022